Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

240 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions.
Badros A, Barlogie B, Morris C, Desikan R, Martin SR, Munshi N, Zangari M, Mehta J, Toor A, Cottler-Fox M, Fassas A, Anaissie E, Schichman S, Tricot G. Badros A, et al. Among authors: zangari m. Blood. 2001 May 1;97(9):2574-9. doi: 10.1182/blood.v97.9.2574. Blood. 2001. PMID: 11313244 Free article. Clinical Trial.
Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities.
Desikan R, Barlogie B, Sawyer J, Ayers D, Tricot G, Badros A, Zangari M, Munshi NC, Anaissie E, Spoon D, Siegel D, Jagannath S, Vesole D, Epstein J, Shaughnessy J, Fassas A, Lim S, Roberson P, Crowley J. Desikan R, et al. Among authors: zangari m. Blood. 2000 Jun 15;95(12):4008-10. Blood. 2000. PMID: 10845942 Free article. Clinical Trial.
Preceding chemotherapy, tumour load and age influence engraftment in multiple myeloma patients mobilized with granulocyte colony-stimulating factor alone.
Desikan KR, Tricot G, Munshi NC, Anaissie E, Spoon D, Fassas A, Toor A, Zangari M, Badros A, Morris C, Vesole DH, Siegel D, Jagannath S, Barlogie B. Desikan KR, et al. Among authors: zangari m. Br J Haematol. 2001 Jan;112(1):242-7. doi: 10.1046/j.1365-2141.2001.02498.x. Br J Haematol. 2001. PMID: 11167811 Free article.
Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients.
Barlogie B, Desikan R, Eddlemon P, Spencer T, Zeldis J, Munshi N, Badros A, Zangari M, Anaissie E, Epstein J, Shaughnessy J, Ayers D, Spoon D, Tricot G. Barlogie B, et al. Among authors: zangari m. Blood. 2001 Jul 15;98(2):492-4. doi: 10.1182/blood.v98.2.492. Blood. 2001. PMID: 11435324 Free article. Clinical Trial.
Thalidomide in the management of multiple myeloma.
Barlogie B, Zangari M, Spencer T, Fassas A, Anaissie E, Badros A, Cromer J, Tricot G. Barlogie B, et al. Among authors: zangari m. Semin Hematol. 2001 Jul;38(3):250-9. doi: 10.1016/s0037-1963(01)90017-4. Semin Hematol. 2001. PMID: 11486313 Review.
Results of autologous stem cell transplant in multiple myeloma patients with renal failure.
Badros A, Barlogie B, Siegel E, Roberts J, Langmaid C, Zangari M, Desikan R, Shaver MJ, Fassas A, McConnell S, Muwalla F, Barri Y, Anaissie E, Munshi N, Tricot G. Badros A, et al. Among authors: zangari m. Br J Haematol. 2001 Sep;114(4):822-9. doi: 10.1046/j.1365-2141.2001.03033.x. Br J Haematol. 2001. PMID: 11564069 Free article.
Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications.
Zangari M, Saghafifar F, Anaissie E, Badros A, Desikan R, Fassas A, Mehta P, Morris C, Toor A, Whitfield D, Siegel E, Barlogie B, Fink L, Tricot G. Zangari M, et al. Blood Coagul Fibrinolysis. 2002 Apr;13(3):187-92. doi: 10.1097/00001721-200204000-00003. Blood Coagul Fibrinolysis. 2002. PMID: 11943931 Clinical Trial.
240 results